Thus, our data suggest that sampling either the primary (pre- or posttherapeutical tumor tissue) or metastatic lesion may be valid for the initial evaluation of KRAS mutation status for predicting the response to anti-EGFR treatment and guiding clinical decisions. This evidence concerns the gene KRAS and neoplasm.